<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00701545</url>
  </required_header>
  <id_info>
    <org_study_id>CSLBC-HP-PM-001</org_study_id>
    <nct_id>NCT00701545</nct_id>
  </id_info>
  <brief_title>A Canadian Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced)</brief_title>
  <official_title>A Canadian, Multi-center, Prospective, Open-label, Observational, Pharmacovigilance Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced) in Patients Transitioning From Treatment With Currently Available Humate-P®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSL Behring</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      As part of CSL Behring Canada's continued commitment to ensuring the safety of the new low
      volume preparation of Humate-P®, CSL Behring Canada proposes to conduct a prospective,
      multi-center structured data collection of routine management of patients with von Willebrand
      disease treated with Humate P® ivr in Canada. The surveillance will be non-interventional and
      non-experimental. During the observation period, the routine medical care of the patient will
      be documented.

      It is expected that there will be no difference in the safety and tolerability of Humate-P®
      ivr compared to Humate-P®
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety and tolerability of Humate-P® (reported adverse events)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To capture efficacy data on Humate-P® ivr: • supporting clinical management of bleeding episode or surgery • incidence of relevant bleeding episodes</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">21</enrollment>
  <condition>Von Willebrand Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Patients with von Willebrand disease treated with Humate P® ivr in Canada</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with von Willebrand disease treated with Humate P® ivr in Canada
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients of any age;

          -  Patients who are suffering with von Willebrand disease previously treated with
             Humate-P®;

          -  Patients who are able to communicate well with the Investigator and his/her
             representatives;

          -  Patients who are able and agreeing to comply with all study requirements;

          -  Patients who have provided written signed and dated informed consent prior to any
             study procedures being performed.

        Exclusion Criteria:

          -  Patients who have received any investigational drug ≤ 4 weeks prior to starting study
             drug or who have not recovered from side effects of such therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David G. Barnes, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>CSL Behring Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.cslbehring.com/clinical-trials/contact-us.htm?registryRefNum=NCT00701545&amp;registryName=ctgov</url>
    <description>Click here to request more information about this study</description>
  </link>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2008</study_first_submitted>
  <study_first_submitted_qc>June 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2008</study_first_posted>
  <last_update_submitted>February 10, 2011</last_update_submitted>
  <last_update_submitted_qc>February 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr David G. Barnes</name_title>
    <organization>CSL Behring Canada, Inc.</organization>
  </responsible_party>
  <keyword>von Willebrand disease</keyword>
  <keyword>VWD, Humate-P®</keyword>
  <keyword>Infusion volume reduced</keyword>
  <keyword>ivr</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Von Willebrand Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

